Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Required: KRAS mutation in codon 12 (12A, C, D, R, S, V) or 13 (13D)

All patients with mutant KRAS status in either codon 12 (12A, C, D, R, S, V) or 13 (13D) will be included.

Must have received: anti-PD-1/PD-L1 therapy — frontline (NSCLC)

NSCLC, progressing on frontline anti-PD-1/PD-L1 containing therapy

Must have received: any prior treatment — any (PDAC)

PDAC patients who failed one prior treatment

Cannot have received: anti-CD38 therapy (daratumumab)

Daratumumab or other anti-CD38 therapies

Cannot have received: anti-PD-1/PD-L1 therapy

Exception: for NSCLC: anti-PD-1/PD-L1 therapy or second line therapy ≤4 weeks prior to registration

For NSCLC: anti-PD-1/PD-L1 therapy or second line therapy ≤4 weeks prior to registration

Cannot have received: anti-PD-1 therapy

for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways

Cannot have received: anti-PD-L1 therapy

for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways

Cannot have received: anti-CTLA-4 therapy

for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways

Cannot have received: T cell co-stimulation or checkpoint pathway inhibitor

for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways

Cannot have received: chemotherapy

Exception: ≤4 weeks prior to registration

Chemotherapy ≤4 weeks prior to registration

Cannot have received: surgery

Exception: ≤3 weeks prior to registration

Surgery ≤3 weeks prior to registration

Cannot have received: focal radiation therapy

Exception: within 14 days prior to first study treatment (except palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma)

Focal radiation therapy within 14 days prior to first study treatment with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma

Cannot have received: complementary medications

Exception: <2 weeks prior to first study treatment

Treatment with complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within <2 weeks prior to first study treatment

Cannot have received: live/attenuated vaccine

Exception: within 30 days of first study treatment

Treatment with any live / attenuated vaccine within 30 days of first study treatment